Home / NCIMI partners one step closer to large scale AI adopti…
NCIMI partners one step closer to large scale AI adoption
April 29, 2021
Caristo Diagnostics CaRi-Heart®
Working closely with the British Heart Foundation, Caristo has received CE-marking for its innovation: CaRi-Heart®️ cardiovascular risk prediction service.
It means patients in the UK and Europe can now benefit from personalised, accurate predictions of their risk of heart attack based on coronary inflammation.
The first-of-its-kind technology, CaRi-Heart® has the power to detect ‘invisible’ risk in people with possible heart disease by using routine heart scans already performed in clinical practice.
Optellum Virtual Nodule Clinic
Meanwhile, Optellum has received national press attention for its lung cancer diagnostic technology, Virtual Nodule Clinic.
Coverage on with inews and BBC South Today sets out what this could mean for the NHS and patients in the UK.
Farewell from Claire Bloomfield
September 9, 2021
Final words from our departing CEO, Claire Bloomfield As I leave NCIMI today, I am reflecting on all the hard…
NCIMI events, speaking engagements, conferences and webinars
September 1, 2021
Optellum collaborating with Johnson & Johnson
August 18, 2021
Ecosystem approach will bring AI benefits to the clinical front line
August 12, 2021